{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:25:46Z","timestamp":1794097546572,"version":"4.8.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is rapidly expanding for diabetes and weight loss. However, limited research exists regarding its effect on postoperative surgical outcomes, particularly in higher-risk patients with comorbidities such as diabetes and obesity. We sought to analyze the effect of GLP-1 RA use on postoperative complications in diabetic patients stratified by BMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A retrospective, observational cohort analysis was conducted in all patients diagnosed with type 1 or type 2 diabetes mellitus undergoing a surgical procedure between February 2020 to July 2023 at a multicenter quaternary-care health care system. Patients with and without an active GLP-1 RA prescription were compared in each of 4 cohorts: normal weight (BMI 18.5\u201324.9\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), overweight (25\u201329.9), obese (30\u201340), and morbidly obese (&gt;40). Outcomes examined were dehiscence, infection, hematoma, and bleeding within 180\u2009days after surgery, and 30-day readmission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>From 72,578 procedures in 21,544 diabetic patients, 23% of patients were classified as normal weight, 34% overweight, 35% obese, and 8% morbidly obese, with active GLP-1 RA use in 15.4%, 24.4%, 33.8%, and 46.5%, respectively. Mean A1C of GLP-1 RA users was significantly higher than nonusers in all cohorts. Active GLP-1 RA cohorts demonstrated a significantly reduced relative risk of postoperative wound dehiscence in normal-weight (0.59), overweight (0.60), obese (0.67), and morbidly obese (0.40) cohorts; a significantly reduced risk of readmission in all cohorts (0.74, 0.82, 0.62, 0.55, respectively); and a significantly reduced risk of postoperative hematoma in obese patients (0.19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Active perioperative GLP-1 RA use was associated with significant reductions in readmission and wound dehiscence in diabetic patients across weight categories, despite higher A1C levels, with the greatest reductions in morbidly obese patients. These findings suggest a potential wound healing benefit, with promising implications for diabetic and obese\/overweight patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/sap.0000000000004657","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:00:10Z","timestamp":1771020010000},"page":"S192-S197","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Active GLP-1 RA Use Is Associated With Lower Rates of Surgical Complications Across Diabetic BMI Cohorts"],"prefix":"10.1097","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0760-7427","authenticated-orcid":false,"given":"Sophia","family":"Salingaros","sequence":"first","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine H.","family":"Rohde","sequence":"additional","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Spector","sequence":"additional","affiliation":[{"name":"Division of Plastic and Reconstructive Surgery, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"bib3-20260515","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review","volume":"5","author":"Honigberg","year":"2020","journal-title":"JAMA Cardiol"},{"key":"bib4-20260515","first-page":"8","article-title":"Poll: roughly 12% of US adults have used a GLP-1 drug, even if unaffordable","volume":"332","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"bib5-20260515","doi-asserted-by":"crossref","first-page":"NP279","DOI":"10.1093\/asj\/sjad364","article-title":"Practice patterns and perspectives of the off-label use of GLP-1 agonists for cosmetic weight loss","volume":"44","author":"Han","year":"2024","journal-title":"Aesthet Surg J"},{"key":"bib6-20260515","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamasurg.2024.0111","article-title":"Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia","volume":"159","author":"Sen","year":"2024","journal-title":"JAMA Surg"},{"key":"bib8-20260515","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.soard.2024.08.033","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"20","author":"Kindel","year":"2024","journal-title":"Surg Obes Relat Dis"},{"key":"bib9-20260515","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"bib10-20260515","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"bib11-20260515","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1126\/science.adn4128","article-title":"The benefits of GLP-1 drugs beyond obesity","volume":"385","author":"Drucker","year":"2024","journal-title":"Science"},{"key":"bib12-20260515","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"bib13-20260515","first-page":"CD012990","article-title":"GLP-1 receptor agonists for Parkinson's disease","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"bib14-20260515","doi-asserted-by":"crossref","first-page":"107220","DOI":"10.1016\/j.parkreldis.2024.107220","article-title":"GLP-1 receptor agonists for Parkinson's disease: an updated meta-analysis","volume":"130","author":"Albuquerque","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"bib15-20260515","doi-asserted-by":"crossref","first-page":"107312","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review\u2014glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"key":"bib16-20260515","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/SLA.0000000000006614","article-title":"Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes","volume":"281","author":"Aschen","year":"2025","journal-title":"Ann Surg"},{"key":"bib18-20260515","doi-asserted-by":"crossref","first-page":"100375","DOI":"10.1016\/j.metop.2025.100375","article-title":"Obesity: prevalence, causes, consequences, management, preventive strategies and future research directions","volume":"27","author":"Ahmed","year":"2025","journal-title":"Metabol Open"},{"key":"bib19-20260515","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1021\/acsptsci.9b00048","article-title":"Inventing liraglutide, a glucagon-like peptide-1 analogue, for the treatment of diabetes and obesity","volume":"2","author":"Knudsen","year":"2019","journal-title":"ACS Pharmacol Transl Sci"},{"key":"bib20-20260515","first-page":"10.15620\/cdc\/174616","article-title":"GLP-1 injectable use among adults with diagnosed diabetes: United States, 2024","author":"Vahratian","year":"2025","journal-title":"NCHS Data Brief"},{"key":"bib23-20260515","article-title":"Preoperative hemoglobin A1C, glycemic status, and postoperative outcomes in general surgery [published online November 5, 2025]","author":"Schaschinger","journal-title":"JAMA Surg"},{"key":"bib24-20260515","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2337\/dc13-1929","article-title":"Preoperative A1C and clinical outcomes in patients with diabetes undergoing major noncardiac surgical procedures","volume":"37","author":"Underwood","year":"2014","journal-title":"Diabetes Care"},{"key":"bib25-20260515","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.arth.2023.05.071","article-title":"Does semaglutide use decrease complications and costs following total knee arthroplasty?","volume":"38","author":"Magruder","year":"2023","journal-title":"J Arthroplasty"},{"key":"bib26-20260515","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.arth.2023.12.023","article-title":"Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions","volume":"39","author":"Magruder","year":"2024","journal-title":"J Arthroplasty"},{"key":"bib27-20260515","doi-asserted-by":"crossref","first-page":"14791641251322909","DOI":"10.1177\/14791641251322909","article-title":"The impact of semaglutide on wound healing in diabetes related foot ulcer patients: a TriNetX database study","volume":"22","author":"Lewis","year":"2025","journal-title":"Diab Vasc Dis Res"},{"key":"bib28-20260515","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/j.jvs.2025.03.034","article-title":"GLP-1 receptor agonists are associated with fewer major complications, hospital admissions, and better venous ulcer healing","volume":"81","author":"Go","year":"2025","journal-title":"J Vasc Surg"},{"key":"bib29-20260515","first-page":"100612","article-title":"Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: a propensity-score matched analysis","volume":"22","author":"Goldman","year":"2025","journal-title":"N Am Spine Soc J"},{"key":"bib30-20260515","doi-asserted-by":"crossref","first-page":"100746","DOI":"10.1016\/j.jhsg.2025.100746","article-title":"Impact of perioperative glucagon-like peptide-1 receptor agonists on postoperative outcomes following carpal tunnel release","volume":"7","author":"Bank","year":"2025","journal-title":"J Hand Surg Glob Online"},{"key":"bib31-20260515","doi-asserted-by":"crossref","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"bib32-20260515","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.metabol.2013.04.010","article-title":"GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways","volume":"62","author":"Aronis","year":"2013","journal-title":"Metabolism"},{"key":"bib33-20260515","doi-asserted-by":"crossref","first-page":"e2405987","DOI":"10.1002\/advs.202405987","article-title":"Liraglutide promotes diabetic wound healing via Myo1c\/Dock5","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"bib34-20260515","doi-asserted-by":"crossref","first-page":"86898","DOI":"10.5493\/wjem.v14.i1.86898","article-title":"Understanding wound healing in obesity","volume":"14","author":"Cotterell","year":"2024","journal-title":"World J Exp Med"},{"key":"bib35-20260515","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0022034509359125","article-title":"Factors affecting wound healing","volume":"89","author":"Guo","year":"2010","journal-title":"J Dent Res"},{"key":"bib36-20260515","doi-asserted-by":"crossref","first-page":"339","DOI":"10.21037\/jss-24-152","article-title":"Preoperative optimization of obese spine patients with GLP-1 receptor agonists: enhancing surgery and improving outcomes","volume":"11","author":"Barkyoumb","year":"2025","journal-title":"J Spine Surg"},{"key":"bib37-20260515","doi-asserted-by":"crossref","first-page":"10449","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"bib38-20260515","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00464-024-11308-6","article-title":"GLP-1 receptor agonists are a transformative prehabilitation tool for weight loss in obese patients undergoing elective hernia repair","volume":"39","author":"Spurzem","year":"2025","journal-title":"Surg Endosc"},{"key":"bib39-20260515","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamasurg.2025.0001","article-title":"Neoadjuvant semaglutide, bariatric surgery weight loss, and overall outcomes","volume":"160","author":"Mathur","year":"2025","journal-title":"JAMA Surg"},{"key":"bib40-20260515","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1007\/s11695-025-08136-5","article-title":"Surgical outcomes in patients with preoperative GLP-1 therapy: a retrospective analysis","volume":"35","author":"Poljo","year":"2025","journal-title":"Obes Surg"},{"key":"bib41-20260515","doi-asserted-by":"crossref","first-page":"103408","DOI":"10.1016\/j.eclinm.2025.103408","article-title":"Evaluation of safety of preoperative GLP-1 receptor agonists in patients undergoing elective surgery: a systematic review, meta-analysis and meta-regression","volume":"87","author":"Kamarajah","year":"2025","journal-title":"EClinicalMedicine"},{"key":"bib42-20260515","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/asj\/sjae085","article-title":"Prevalence patterns of body contouring procedures among injectable glucagon-like peptide-1 receptor agonist users","volume":"44","author":"Toms","year":"2024","journal-title":"Aesthet Surg J"},{"key":"bib43-20260515","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/asj\/sjae241","article-title":"Semaglutide and postoperative outcomes in nondiabetic patients following body contouring surgery","volume":"45","author":"Lewis","year":"2025","journal-title":"Aesthet Surg J"},{"key":"bib44-20260515","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bjps.2025.09.028","article-title":"Breast implant explantation with mastopexy in patients using GLP-1 receptor agonizts: a retrospective comparative analysis","volume":"111","author":"Friedman","year":"2025","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"bib45-20260515","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/NT.0000000000000092","article-title":"Body mass index: obesity, BMI, and health: a critical review","volume":"50","author":"Nuttall","year":"2015","journal-title":"Nutr Today"},{"key":"bib46-20260515","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/oby.20408","article-title":"Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model","volume":"21","author":"Thomas","year":"2013","journal-title":"Obesity (Silver Spring)"}],"container-title":["Annals of Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SAP.0000000000004657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:00:58Z","timestamp":1778832058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SAP.0000000000004657"}},"subtitle":["A Retrospective Analysis of 72,578 Surgical Encounters"],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":40,"journal-issue":{"issue":"5S","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/sap.0000000000004657","relation":{},"ISSN":["1536-3708","0148-7043"],"issn-type":[{"value":"1536-3708","type":"electronic"},{"value":"0148-7043","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}